Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: April 7, 2003
Last updated: June 16, 2014
Last verified: December 2012
This phase I trial is studying the side effects and best dose of combination chemotherapy in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as docetaxel and 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Condition Intervention Phase
Recurrent Prostate Cancer
Stage IV Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Drug: tanespimycin
Drug: docetaxel
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC# 330507) in Combination With Docetaxel in Patients With Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Maximum tolerated dose determined by dose-limiting toxicities assessed using the NCI Common Toxicity Criteria (CTC) version 2.0 [ Time Frame: 28 days ]

Enrollment: 80
Study Start Date: February 2003
Study Completion Date: March 2010
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group I
Patients receive docetaxel IV over 1 hour and 17-AAG IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Drug: tanespimycin
Given IV
Other Name: 17-AAG
Drug: docetaxel
Given IV
Other Names:
  • RP 56976
  • Taxotere
  • TXT
Experimental: Group II
Patients receive docetaxel IV over 30 minutes and 17-AAG as in group 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: tanespimycin
Given IV
Other Name: 17-AAG
Drug: docetaxel
Given IV
Other Names:
  • RP 56976
  • Taxotere
  • TXT

Detailed Description:


I. Determine the maximum tolerated dose of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) administered with docetaxel in patients with progressive metastatic prostate cancer or other progressive metastatic or unresectable solid tumors.

II. Determine the pharmacokinetics of this regimen in these patients.

OUTLINE: This is a dose-escalation study of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG). Patients are assigned to 1 of 2 treatment groups.

Group 1: Patients receive docetaxel IV over 1 hour and 17-AAG IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Group 2: Patients receive docetaxel IV over 30 minutes and 17-AAG as in group 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients per group receive escalating doses of 17-AAG until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 20 additional patients (10 per group) are treated at the MTD.

Patients are followed every 2-3 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed metastatic or unresectable malignancy for which standard curative or palliative therapy does not exist or is no longer effective
  • Progressive disease manifested by the following parameters

    • For prostate cancer:

      • Must have castrate, metastatic disease defined by disease progression after surgical castration or treatment with a gonadotropin-releasing hormone (GnRH) analog (testosterone level less than 50 ng/mL)

        • Patients who have not undergone surgical orchiectomy should continue on medical therapies to maintain castrate levels of testosterone
      • Progressive metastatic disease on imaging studies (bone scan, CT scan, or MRI) OR metastatic disease and a rising prostate-specific antigen (PSA)
      • Biochemical progression indicated by at least 3 rising PSA values (obtained at least 1 week apart) from a baseline OR 2 rising PSA values (more than 1 month apart), where the percentage increase over the range of values is at least 25%
      • Patients who have received an antiandrogen as part of first-line hormonal therapy must have shown progression of disease off of the antiandrogen prior to study enrollment
    • For other solid tumors:

      • Development of new lesions or an increase in pre-existing lesions by bone scintigraphy, CT scan, MRI, positron emission tomography, or physical examination
      • Patients whose sole criterion for progression is an increase in a biochemical marker (e.g., carcinoembryonic antigen or CA 15-3) or an increase in symptoms are not eligible
  • Patients with metastatic disease must not be progressing to the extent as to require palliative treatment within 4 weeks of study entry
  • No active brain metastases
  • Performance status - Karnofsky 70-100%
  • More than 6 months
  • WBC at least 3,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST and ALT < 1.5 times ULN
  • PT ≤ 1.1 times ULN
  • Creatinine no greater than 1.4 mg/dL or within ULN
  • Creatinine clearance greater than 55 mL/min
  • No prior history of pulmonary toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine)
  • No dyspnea ≥ grade 2 at rest on room air
  • No requirement for supplementary oxygen therapy or oxygen saturations ≤ 88%
  • No clinically significant pulmonary comorbidities that require medication (e.g., severe chronic obstructive pulmonary disease that could predispose patient to pulmonary toxicity)
  • QTc ≤ 450 msec for male patients (470 for female patients)
  • LVEF > 40% by echocardiogram or MUGA
  • Echocardiogram or MUGA required for patients with any of the following:

    • Myocardial infarction > 1 year ago
    • NYHA class I or II CHF
    • Atrial fibrillation
    • Right or left bundle branch block by EKG
  • No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
  • No myocardial infarction within the past year
  • No active ischemic heart disease within the past year
  • No New York Heart Association (NYHA) class III or IV congestive heart failure (CHF)
  • No poorly controlled angina
  • No uncontrolled dysrhythmia
  • No congenital long QT syndrome
  • No left bundle branch block
  • No other significant cardiac disease
  • No prior history of cardiac toxicity after receiving anthracyclines such as doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No history of severe hypersensitivity reaction to paclitaxel, docetaxel, or polysorbate 80
  • No ongoing or active infection
  • No psychiatric illness or social situation that would preclude study compliance
  • No grade 2 or greater symptomatic peripheral neuropathy
  • No allergy to eggs or egg products
  • No other concurrent uncontrolled illness
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy and recovered
  • No concurrent radiotherapy to sole measurable lesion
  • No prior mantle-field radiotherapy
  • See Disease Characteristics
  • No concurrent surgery for sole measurable lesion
  • Recovered from prior therapy
  • At least 1 week since prior ketoconazole and recovered
  • At least 4 weeks since prior investigational anticancer therapeutic drugs
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No concurrent medications that prolong QTc interval
  • No concurrent medication used to control arrhythmias

    • Calcium blockers and beta blockers allowed
  • No other concurrent investigational agents
  • No other concurrent anticancer agents or therapies (investigational or commercial)
  • No concurrent CYP3A4 inhibitors, including any of the following:

    • Fluconazole
    • Itraconazole
    • Ketoconazole
    • Macrolide antibiotics (azithromycin, clarithromycin, erythromycin, or troleandomycin)
    • Nifedipine
    • Verapamil
    • Diltiazem
    • Cyclosporine
    • Grapefruit juice
  • No concurrent CYP3A4 inducers, including any of the following:

    • Carbamazepine
    • Phenobarbital
    • Phenytoin
    • Rifampin
  • No concurrent herbal extracts or tinctures with CYP3A4 inhibitory activity, including any of the following:

    • Hydrastis canadensis (goldenseal)
    • Hypericum perforatum (St. John's wort)
    • Uncaria tomentosa (cat's claw)
    • Echinacea angustifolia roots
    • Trifolium pratense (wild cherry)
    • Matricaria chamomilla (chamomile)
    • Glycyrrhiza glabra (licorice)
    • Dillapiol
    • Hypericin
    • Naringenin
  • Concurrent CYP3A4 substrates allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00058253

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: David Solit Memorial Sloan Kettering Cancer Center
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00058253     History of Changes
Other Study ID Numbers: NCI-2012-01436
NCI-2012-01436 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
03-006 ( Other Identifier: Memorial Sloan-Kettering Cancer Center )
5878 ( Other Identifier: CTEP )
P30CA008748 ( US NIH Grant/Contract Award Number )
U01CA069856 ( US NIH Grant/Contract Award Number )
Study First Received: April 7, 2003
Last Updated: June 16, 2014

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017